Clinical Trials Browser

Phase 1 × INDUSTRY × HER2-negative Metastatic Breast Cancer × Clear all

NCT05261269 2023-12-13

A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer

Phase 1 Completed

HER2-negative Metastatic Breast Cancer